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Abstract: In vitro cytotoxicity testing has become an integral aspect of drug discovery because it is a convenient, cost-
effective, and predictive means of characterizing the toxic potential of new chemical entities. The early and routine im-
plementation of this testing is testament to its prognostic importance for humans. Although a plethora of assay chemistries 
and methods exist for 96-well formats, few are practical and sufficiently sensitive enough for application in high through-
put screening (HTS). Here we briefly describe a handful of the currently most robust and validated HTS assays for accu-
rate and efficient assessment of cytotoxic risk. We also provide guidance for successful HTS implementation and discuss 
unique merits and detractions inherent in each method. Lastly, we discuss the advantages of combining specific HTS 
compatible assays into multi-parametric, same-well formats.  
INTRODUCTION 
  A significant advance in the field of early medicine was 
Paracelsus’ recognition that all compounds have the capacity 
to be poisonous depending upon dosage [1]. This observa-
tion makes toxicity testing a necessary and critical industry 
practice to identify and define safety thresholds for all new 
potential chemotherapeutics. The advent of in vitro cytotox-
icity testing has greatly streamlined this process and is now 
considered to be a nearly compulsory activity starting at tar-
get validation and continuing through medicinal modifica-
tion. 
  Unlike animal-based toxicology testing, there are clearer 
definitions and greater agreement for what constitutes cyto-
toxicity in vitro. Classically speaking, a compound or treat-
ment is considered to be cytotoxic if it prevents cellular at-
tachment, causes dramatic morphological changes, adversely 
affects replication rate, or leads to a reduction in overall vi-
ability [2]. It should be noted that the manifestation of these 
effects is greatly dependent on length of compound exposure 
and mechanism of cytotoxicity [3].  
  A host of new assays have been described and utilized 
which measure biomarkers of cellular stress or specific sig-
naling events more proximal to initial cytotoxic insult (i.e. 
glutathione, caspases) [4]. These methods offer early indica-
tion of potential cytotoxicity, but are typically relegated to 
secondary screening because they are more difficult to em-
ploy as endpoint assays due to the transient nature of the 
biomarker and kinetic differences associated with cell death 
progression [5, 6]. Therefore assay chemistries predicated 
upon the detection of changes in membrane integrity remain 
the gold standard for in vitro cytotoxicity testing. 
  Many methods exist for the assessment of membrane 
integrity, including several classic dye inclusion, exclusion 
and lysosomal accumulation techniques [7, 8]. Although well 
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validated, these methods are poorly suited for HTS imple-
mentation due to low sensitivity, multiple processing steps or 
miniaturization problems associated with higher plate densi-
ties [9, 10]. Recent advances in reagent formulations ac-
commodate these miniaturized formats and are fully com-
patible with automated dispensing systems and integrated 
detection instruments. These reagents deliver the linearity, 
sensitivity, and robustness (Z’ Values) necessary for prop-
erly interrogating large chemical libraries for cytotoxic risk. 
The most acceptable assay format is known as “add-mix-
measure”, whereby reagent chemistry is delivered directly to 
the test well. 
VIABILITY ASSAYS 
  Viability assays are designed to measure activities attrib-
utable to cellular maintenance and survival. These activities 
are typically metabolic biomarkers such as ATP and mito-
chondrial reductase potential, but can include homeostatic 
“housekeeping” enzyme activities. The underlying assay 
premise is that these activities are directly proportional to 
viable cell number after a treatment period. During relatively 
short incubation periods (8 hr or less), a reduction or com-
plete cessation of these biomarker activities is strongly in-
dicative of overt cytotoxicity by catastrophic membrane 
damage (i.e. primary necrosis) [11]. A reduction in bio-
marker activity compared to control in longer incubations 
indicates either a reduction in normal cellular division rate 
(cell-cycle arrest) or cell death by programmed elimination 
mechanisms such as apoptosis [12, 13]. Because viability 
assays measure the relative number of cells remaining after 
treatment, they offer significant utility even during long 
compound-contact periods (72 hr). 
RESAZURIN REDUCTION 
  The reductive capacity inherent within viable cells can be 
conveniently measured using the redox indicator, resazurin 
[14, 15]. Resazurin is soluble in physiologically buffered 
formulations and can be added directly to growing cultures 
in a one-step, homogeneous addition. Unlike the tetrazolium 
chemistries (2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-5-34    Current Chemical Genomics, 2009, Volume 3  Niles et al. 
carboxanilide-2H-tetrazolium (XTT), (4-[3-4-iodophenyl]- 
2-(4-nitrophenyl)-2H-5-tetrazolio)-1,3-benzene disulfonate) 
WST-1, 5-(3-carboxymethoxyphenyl)-2-(4, 5-dimethyl-thia-
zoly)-3-(4-sulfophenyl) tetrazolium, inner salt (MTS) which 
measure reductive capacity by colorimetric means, the prod-
uct of resazurin reduction (resorufin) can also be measured 
using fluorescence with a fluorometer equipped with 560nm 
excitation and 590nm emission filter set [16-18]. 
  Resorufin product formation as a result of reagent contact 
with viable cells is accumulative and proceeds as a function 
of time. Although somewhat dependent upon cell type, 
metabolic rate and number per well, 2-4 hr of incubation 
with the reagent is typically sufficient to generate signal 
windows for adequate statistical discrimination in HTS.   
(Table 1) Fluorescent resazurin reductase assay chemistries 
have been adapted to 1536 well formats, but are typically 
most useful at lesser plate densities (384 and 96) due to prac-
tical limitations associated with prolonged incubation peri-
ods [19, 20].  
  Resazurin-based chemistries continue to offer significant 
value for HTS because the reagents are robust and stable, 
well-validated, and easy to use. The single greatest attribute 
however, is that resazurin reagents generate amongst the 
most cost-effective data on a per well basis [21]. The major 
disadvantages of employing the chemistry are that the rea-
gent is subject to interferences from compounds with inher-
ent reductive capacity (such as ascorbic acid, glutathione, 
coenzyme A, dithiothreitol etc.) or those with intrinsic fluo-
rescence characteristics [22-24]. Lastly, extended reagent 
incubations (2hr or longer) may produce toxic affects or 
augment affects produced from the experimental compound 
[25]. 
AMINOPEPTIDASE(S) 
  Eukaryotic cells contain a diverse abundance of prote-
olytic activities which act in a concerted effort to maintain 
homeostasis. Recently, a constitutive and conserved amin-
opeptidase-like, proteolytic biomarker profile was identified 
in mammalian cells that can be harnessed for assessing vi-
ability in cell culture [26]. The assay utilizes the cell-
permeant protease substrate glycyl-phenylalanyl-amino-
fluorocoumerin (GF-AFC) that is delivered to wells in a neu-
tral buffer. The substrate, which lacks an amino-terminal 
blocking moiety (i.e. Boc, Ac, or Cbz), can be processed by 
aminopeptidase(s) within the cytoplasm. The AFC product 
released after proteolysis of the substrate is proportional to 
viable cell number. Viability can be measured using a 
fluorometer equipped with a 380-400nm excitation source 
and a 505nm emission filter. 
  The selective detection of viable cells by this method is 
possible because the proteolytic activity towards the GF-
AFC substrate is dependent upon the continued maintenance 
of membrane integrity. This live-cell, proteolytic activity 
decays within seconds after a cytotoxic event, so non-viable 
cells do not contribute appreciably to fluorescence genera-
tion. A 30 minute incubation of reagent and cells at 37ºC is 
typically sufficient for generating a workable signal window, 
but the incubation can be extended without detriment if 
work-flow scheduling does not permit shorter periods. 
  A major advantage of this assay is that it can be conven-
iently multiplexed with other compatible assay chemistries 
to deliver more per-well information (Fig. 1) [27]. This fea-
ture is particularly attractive for normalizing spectrally-
distinct fluorescent or luminescent data sets such as genetic 
report assays [28]. Multiplex applications for viability and 
cytotoxicity will be handled in greater detail in a later section 
of this review. Lastly, although red-shifted from much of the 
problematic coumarin spectrum, the assay is susceptible to 
fluorescence interferences from test compounds [29]. Addi-
tional interferences should be expected from protease inhibi-
tors or from color quenching chemical entities. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Aminopeptidase(s) Assay. CellTiter-Fluor™ (Promega 
Corporation) was added to Jurkat cells treated for 24 hr with serial 
dilutions of paclitaxel. Viability was measured, then Caspase-Glo® 
Reagent added to measure caspase activation. 
 
ATP 
  ATP quantification is a widely accepted method for as-
sessing viability because healthy cells contain closely regu-
lated levels of the biomarker [30, 31]. Non-viable cells not 
only lose the ability to synthesize ATP, but also contain en-
Table 1. Resazurin-Reduction Assay Z’-Factor  
Cells/Well  Mean Fluorescence after 4hr at 37ºC  Standard Deviation  Z’-Factor 
0 455.28  5.76   
500 1074.58  34.67  0.8 
2000 3056.88  125.37  0.85 
2500 3602.1  132.98 0.87 
CellTiter-Blue
® (Promega Corporation) was added and incubated with L929 cells dispensed in 384 well plates. n = 96 for each cell concentration. 
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dogenous ATPases that rapidly deplete the existing ATP. 
Luciferase reaction chemistry is used to quantify ATP, the 
limiting reactant, by generation of a luminescent signal that 
is proportional to viable cell number [32, 33].  
  All commercial ATP quantification reagents contain lu-
ciferase enzyme and luciferin substrate supplied with a lytic 
buffer. Cell lysis is necessary to liberate cellular ATP and is 
typically facilitated by detergents in the buffer. The most 
useful formulations for HTS applications also contain ther-
mostable recombinant luciferase and ATPase inhibitors 
which allow for “glow-type” luminescence that produces a 
sustained signal with a half-life on the order of 5 hr [34, 35]. 
Prolonged maintenance of the luminescent signal allows for 
batch processing of plates and obviates any inter-plate ki-
netic variability. 
  The principle advantages of an ATP assay include that it 
is currently the most rapid and sensitive HTS method avail-
able for assessing viability. For instance, as few as 10 cells 
can be detected in limiting dilution series of eukaryotic cells 
within 10 minutes (Fig. 2). The assays also benefit from rela-
tively high signal to background ratios, which enable routine 
miniaturization into 1536 well formats [36, 37]. Further-
more, luminescence signals are not encumbered by intrinsi-
cally fluorescent test compounds [38]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). ATP Assay Sensitivity. CellTiter-Glo
® (Promega Corpo-
ration) was added and mixed with Jurkat cells in a 384 well plate. 
Luminescence was measured with a Wallac Victor™ after 10 min-
utes of incubation.  
 
  Despite an abundance of advantages for HTS implemen-
tation, ATP assays also carry liabilities. Because the ATP-
dependent luciferase reaction rate is susceptible to tempera-
ture flux, equilibration to constant room temperature is re-
quired to minimize thermal gradients created by plate well 
position (edge-effects). Also, like other metabolic assay 
chemistries used to measure viability, ATP is (rarely) subject 
to positive or negative modulation by test reagents independ-
ent of loss of viability leading to misleading data [39, 40]. 
Lastly, all commercial formulations of ATP-detection chem-
istries are susceptible to luciferase inhibition to various de-
grees by small molecule compounds. Recent evidence sug-
gests that specific formulations may greatly minimize the 
extent of this inhibition [41]. 
CYTOTOXICITY ASSAYS 
  Cytotoxicity assay chemistries are formulated to detect 
loss of membrane integrity associated with cell death. The 
current most useful cytotoxicity biomarkers are constitutive, 
conserved and relatively stable, high-abundance enzymes 
“released” into the extra-cellular environment (culture me-
dium) following loss of membrane integrity. Unlike viability 
assays whereby a decline in cell response is strongly inferred 
to be caused by cell-cycle arrest or death, detection of cyto-
toxic biomarker activities outside the cellular compartment 
after treatment is proof-positive for a compound’s cytotoxic 
effect. Unfortunately, activity-based surrogates of cell death 
have a finite enzymatic half-life, which can limit their utility 
during long compound/cell contact incubations (48-72 hr) [3, 
27]. Enzymatic decay as a function of time in culture me-
dium can lead to underestimation of the absolute level of 
cytotoxicity [27]. The quantitative HTS (qHTS) approach 
eliminates a majority of this error because the kinetics of 
cytotoxicity is intrinsically linked to dose [42]. 
LACTATE DEHYDROGENASE (LDH) 
  LDH activity has a long history as a preferred marker for 
cell death with in vitro cell models [43, 44]. In HTS applica-
tions, the activity of LDH is indirectly measured by an en-
zymatically-coupled reagent chemistry comprised of lactate, 
NAD
+, diaphorase and an appropriate redox dye such as a 
tetrazolium compound or resazurin. Although the result of 
LDH activity can be measured by a change in absorbance, 
fluorescence detection is favored because of greater sensitiv-
ity and the potential to miniaturize to high-density plates. 
  The implementation of LDH assays for cytotoxicity test-
ing in HTS has been historically limited because most com-
mercial assay protocols require a cell-free sample transferred 
into a separate assay plate. Reagents that are compatible with 
viable cells are available to detect release of LDH, thus ena-
bling a single addition homogeneous assay format [45]. Now 
LDH release can be routinely measured in HTS formats after 
a short incubation (10-20 minutes) using a fluorometer 
equipped with a 560nm excitation source and a 590nm col-
lection filter (Fig. 3) [46]. 
 
 
 
 
 
 
 
 
 
 
Fig. (3). LDH Assay Z’-factor Analysis. CytoTox-ONE
® Assay 
reagent (Promega Corporation) was added to HepG2 cells treated 
with 3.125M staurosporine. Medium served as vehicle control. 
 
  LDH assay detection is a robust and cost-effective means 
of assessing cytotoxicity, but is susceptible to background 
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signal from serum sources of LDH found in supplemented 
growth media [47, 48]. Exogenous sources of LDH greatly 
elevate background values and negatively impact the overall 
signal window. This experimental detriment can be largely 
mitigated by careful pre-screening of serum sources for cell 
culture prior to LDH assay. LDH assays are also subject to 
assay artifacts by compounds that inhibit the LDH activity 
and by standard fluorescence and color quenching interfer-
ences [49-51].  
PROTEASE(S) 
  A specific proteolytic profile associated with cell death 
has been recently identified and can be measured in a man-
ner similar to LDH assays [26]. This method employs se-
quence-specific (Ala-Ala-Phe), fluorogenic or luminogenic 
peptide substrates delivered directly into assay wells via a 
buffered vehicle. The proteolytic activities present in viable 
cells are not detected by this method because normally com-
partmentalized proteases are not in contact with the imper-
meant substrates. However, protease(s) released into the cul-
ture medium as a result of cell death cleave the substrates 
releasing a detectible reporting molecule. The fluorescent 
format of the assay utilizes the highly-efficient rhodamine 
110 (R110) fluorophore which is measured in as short as 30 
minutes by a fluorometer with 485nm excitation and 520-
30nm emission filters [52, 53]. The luminescent format em-
ploys an engineered luciferase formulation to detect the lu-
ciferin product of cleavage thereby generating a glow-type 
signal which peaks at 15-20 minutes, stably persists for 3-4 
hr, and is measured by standard luminometry. 
  Dead cell protease detection is advantageous in HTS and 
secondary screening applications because of improved sensi-
tivity, linearity with respect to different degrees of cytotoxic-
ity, reduction in background and artifactual hits, and choice 
in detection format (Fig. 4). These attributes allow the tech-
nology to be applied in 1536 well formats as easily as in 
lower density plates [54]. The dead cell protease detection 
method is subject to enzymatic activity decay due to the ki-
netics of cytotoxicity, biomarker inhibition, and standard 
interferences associated with the detection molecules. 
 
 
 
 
 
 
 
 
Fig. (4). Protease Assay Sensitivity and Linearity. CytoTox-
Glo™ (Promega Corporation) was added to serial dilutions of vi-
able and non-viable Jurkat cells and luminescence measured after 
30 minutes. 
 
MULTIPLEXED VIABILITY AND CYTOTOXICITY 
ASSAYS 
  The single parameter assays described above offer con-
venient and predictive methods to view the cytotoxic land-
scape of chemical libraries. When certain combinations of 
the assays are added as same-well multiplexes however, they 
provide not only complementary but additive benefit [55]. 
Although the concept of multiplexed screening is well ap-
preciated for image-based technologies, it is emerging as a 
more viable option for plate-based, homogeneous assays 
because implementation is simple, accessible, and cost effec-
tive [56]. 
  Reagent compatibility is a major consideration in same-
well multiplexing. There is an absolute requirement that in-
dividual signal readouts are distinct and can be parsed for 
meaningful data set analysis. Also, reagent formulations 
must not compromise functional aspects of the chemistries. 
For instance, lytic assays for ATP measurement or caspase 
activation must be conducted in a sequence-specific order 
after first measuring experimental cytotoxicity. 
  Several informative combinations of viability and cyto-
toxicity chemistries are currently employed in HTS formats 
to mitigate false determinations. These multiplexes address 
systematic error caused either by disparate cell numbers de-
livered to assay wells or random compound interferences 
with reporter molecules [55]. Except in cases of cell-cycle 
arrest prior to loss of membrane integrity, or long term expo-
sure models, measures of viability and cytotoxicity are in-
versely proportional (Fig. 5). Therefore, non-conforming 
data sets can easily “flag” problem compounds for further 
analysis by orthogonal methods [57]. 
FLUORESCENT/FLUORESCENT ASSAYS 
  Several classic examples of fluorescent viability and cy-
totoxicity assays are known [58]. These methods rely on an 
impermeant DNA intercalating dye which labels cells with 
damaged membranes and a permeable dye that is sequestered 
inside viable cells after esterase cleavage of a labeling group. 
Variations of these traditional chemistries are rarely em-
ployed where total fluorescence from assay wells is meas-
ured, because of poor sensitivity from simple stoichiometric 
dye binding events in the non-viable cell population and req-
uisite washes required for removal of unbound dye and se-
rum-derived esterases. Stable, non-viable cell esterase activ-
ity is particularly problematic for assay utility as it greatly 
impacts assay background values and constricts signal win-
dows. 
  A new, more amenable method for HTS environments 
combines the protease substrates for viability and cytotoxic-
ity allowing for simultaneous measurement of viable and 
non-viable cell populations (Fig. 6). This method delivers 
broad linear responses (0-50,000 cells/well) and can measure 
as little as a 2% change in viability in both the AFC and 
R110 channels [59]. Furthermore, the reagent can be concen-
trated and delivered into assay wells in a substantially re-
duced volume to accommodate a third spectrally distinct 
reagent. 
  Triplexes created by uniting the fluorescent viability and 
cytotoxicity multiplex with luminescent chemistries are ad-
vantageous for several reasons. First, it is possible to conduct 
immediate confirmation testing of apparent cytotoxic com-
pounds in the same well by leveraging the statistical power 
of orthogonal detection of viability (viable cell aminopepti-
dase, dead cell protease and ATP biomarkers). The economy 
of this consolidated testing is noteworthy in terms of 
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Fig. (5). Single- and Multi-parameter Viability and Cytotoxicity Assays. CellTiter-Blue
®, CytoTox-ONE™, CellTiter-Glo
®, MultiTox-
Fluor, MultiTox-Glo and CytoTox-Glo™ Reagents (Promega Corporation) were added to Jurkat cells treated for 6 hr with serial dilutions of 
ionomycin and signals measured as described in technical literature. 
compound usage, culture set up, and operator man-hours. 
Second, the mechanism of cell death can often be elucidated 
when combined with caspase detection reagents, allowing 
for partial characterization of a compound’s potential. It 
should be noted however, that caspase activity can be tran-
sient and immeasurable in long-term experiments due to the 
kinetics of apoptosis and caspase biomarker decay. There-
fore, caspase-negative data sets should be rescreened at mul-
tiple compound exposure periods. This type of characteriza-
tion of pathway dependent cytotoxicity is useful for contin-
ued annotation of a library, because compounds causing ne-
crotic profiles at micromolar concentrations are rarely thera-
peutically useful and may offer unacceptable cytotoxic risk. 
And third, viability and cytotoxicity can be used to normal-
ize luminescent data from other assays (Fig. 7). Single pa-
rameter genetic reporter responses are susceptible to experi-
mental variation due to differential transfection efficiencies, 
cell number delivered to the well (clumping) or to cytotoxic-
ity caused by the test compound [55]. Viability and cytotox-
icity data can therefore help reconcile aberrant data points or 
explain decreases in genetic reporter signals due to cell 
death. 
FLUORESCENT/LUMINESCENT ASSAYS 
  Mixed detection combinations of the protease biomarkers 
are also available that offer benefit in screening applications. 
In this method, viability is measured first by the addition of 
the GF-AFC reagent followed by the addition of the lumino-
genic dead cell reagent chemistry. The use of disparate de-
tection platform methodologies is known to greatly reduce 
the statistical potential for assay interferences associated 
with reporter molecules [60]. Therefore this combination of 
chemistries is favored if a library is uncharacterized with 
regard to the relative abundance of luminogenic inhibitors or 
which may cause fluorescence interference. Unlike the fluo-
rescence/fluorescence multiplex, fewer convenient triplex 
options exist. For example, the chemistry can be configured 
with a fluorogenic caspase activation chemistry (R110 
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Fig. (6). Fluorescent/Fluorescent and Fluorescent Luminescent Viability and Cytotoxicity Assays. MultiTox-Fluor or MultiTox-Glo 
Reagents (Promega Corporation) were added to a 1536 well plate after Jurkat cells had been treated with 30g/ml digitonin or vehicle. Each 
well is represented as a ratio of the viable and non-viable values measured using the chemistries. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Multi-Parametric Viability Assays Paired with Caspase Assays. Jurkat cells were plated in 384 well plates and treated with serial 
dosages of etoposide for 6hr. MultiTox-Fluor™ or MultiTox-Glo Reagents (Promega Corporation) were added to the plates and viability and 
cytotoxicity values measured. Apo-ONE
® or Caspase-Glo
® Reagents (Promega Corporation) were then added and caspase activation meas-
ured. 
fluorophore) to deliver data relating to possible induction of 
apoptosis (Fig. 7A) [61, 62]. Again, negative caspase induc-
tion results should be verified by rescreening to verify ne-
crotic response profiles. 
LUMINESCENT/LUMINESCENT ASSAYS 
  Fully-luminescent formats are highly desirable for HTS 
environments because of the aforementioned advantages 
over fluorescent methods. Another remarkable feature of 
luminogenic assays is the persistent and stable glow-type 
signal produced after reagent addition (Fig. 8). This attribute 
can be harnessed to produce both viability and cytotoxicity 
values from the same well. In this method, the non-lytic, 
luminogenic cytotoxicity assay chemistry is first delivered to 
the assay well and cytotoxicity measured. Next, a lytic agent 
is added to assay wells to artificially release the remaining 
dead cell protease from viable cells. The net signal derived 
after complete lysis reflects the contribution of all the cells in 
the assay well. Because the luminescent signal is additive 
and proportional, the viable cell population can be indirectly 
determined by subtracting the cytotoxic values from the total 
values. This method is particularly useful for determining 
cytotoxicity in long incubation protocols where dead cell 
biomarker activity may not fully reflect actual cytotoxicity. 
One caveat of this method is that both viability and cytotox-
icity measurements utilize the same biomarker and are sub-
ject to the same interferences. 
SUMMARY AND CONCLUSIONS 
 In  vitro cytotoxicity testing technologies for HTS con-
tinue their refinement on many fronts. High Content Screen-
ing (HCS) and label-free methods have gained some degree 
of popular following recently, but require expensive instru-
mentation, complicated analysis software packages and offer 
relatively low throughput. With burgeoning costs associated 
with drug discovery efforts, straight-forward, validated, ho-
mogeneous assay chemistries remain the choice as a simple 
and cost-effective means of assessing cytotoxic burden. 
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  Depending upon the goals of the screen, either viability 
or true cytotoxicity assay chemistries can be employed. Cy-
totoxicity assays based on membrane integrity changes are 
positive-readout assays most typically indicated for shorter-
term exposure models (48 hr or less). These assays may not 
always accurately estimate the absolute degree of early or 
late stage cytotoxicity due to the kinetics of biomarker emer-
gence or degradation. Viability assays measure the level of 
biomarker activity inversely correlated with cytotoxicity and 
therefore may be used at any endpoint during a com-
pound/cell incubation period. 
  Each biomarker of viability and cytotoxicity has advan-
tages and disadvantages. The choice of which surrogate of 
health or death to use is greatly influenced by the available 
detection format and extent of assay time required to reach a 
result (Table 2). Fluorescent formats require short to lengthy 
incubations with the sample whereas luminescent formats 
tend to deliver maximal signal windows in a rapid but pro-
longed fashion. Luminescent formats offer additional utility 
over fluorescent methods with regard to detection sensitivity, 
but are also typically more costly to use on a per well basis. 
  All assay chemistries are subject to experimental error or 
interferences which can lead to false interpretation of data 
sets. Multiplexed combinations of compatible assays offer a 
convenient and cost-effective manner to address variation 
(by response normalization), flag non-conforming orthogo-
nal data points and increase per well content. Although 
greatly informative, special attention should be paid to ex-
perimental design and the interpretation of multiplexed data 
sets due to the transient or kinetic nature of mechanistic 
biomarkers. 
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